Intracranial infectious aneurysms (IIAs) are a rare subgroup of intracranial aneurysms. Often erroneously termed mycotic aneurysms, these lesions most often result from infectious endocarditis and involve the distal anterior cortical circulation. Diagnosis typically follows headaches or septic infarcts, although increasing numbers of lesions are found incidentally, during screening protocols for infectious endocarditis. Open surgical treatment was previously the mainstay of treatment; however, these IIAs are often fusiform and quite fragile, making open surgical obliteration difficult and typically requiring lesion trapping. Current treatment techniques more commonly involve endovascular coil embolization or parent vessel occlusion. Many of these lesions occur distally, in or around the eloquent cortex, making embolization potentially dangerous. We present cases that highlight the use of super-selective provocative testing with sodium amobarbital and lidocaine, to help clarify and predict the risk of parent vessel occlusion in IIAs located in the eloquent cortex.
Introduction
Intracranial infectious aneurysms (IIAs) represent an estimated 5% of all intracranial aneurysms. 1 The majority of IIAs are the result of bacterial pathogens, not fungal organisms (the older term mycotic aneurysm developed from the description of these aneurysms' shapes). 2, 3 Common causative conditions include infective endocarditis and poor dental hygiene; an estimated 1-10% of patients with infective endocarditis may harbor an IIA. 4 The majority of IIAs are seen in the anterior circulation, particularly in the distal branches of the middle cerebral artery (MCA). 5 The estimated risk of rupture for an IIA is low, commonly reported at 2-10%; 6 however, the associated mortality of a ruptured IIA is 30-80%. 7 No guidelines exist to aid therapeutic decisions with IIAs. Antibiotics remain a mainstay of treatment with or without direct IIA or parent vessel occlusion. Historically, open surgical methods such as aneurysm clipping, trapping, wrapping, bypass or direct excision with parent vessel re-anastomosis provide the mainstays of occlusion; however, open surgical treatment can be quite difficult, as these IIAs are typically fusiform or harbor wide necks with fragile walls. Endovascular treatment now likely represents the most common method of occlusion. 1 Endovascular techniques typically include either direct IIA occlusion in more proximal locations, or parent vessel occlusion, in distal lesions. 1 Concerns of persistent infection with endovascular treatment appear unfounded, as a large review of reported cases of IIA treatment (287 total cases with 46 endovascular treatments) failed to demonstrate any post-procedural infections in the endovascular cases. 5 Endovascular treatment of distal IIAs in the eloquent cortex presents a particular dilemma, as parent vessel occlusion may result in significant neurologic dysfunction. Superselective provocative testing is a technique using sodium amobarbital injected into a target vessel, with the patient awake, to determine the safety of vascular sacrifice. 8 This method was described for the embolization of tumors and arteriovenous malformations, but rarely was it described in the treatment of distal IIAs. 9 In this report, we have described the use of superselective awake provocative testing in the treatment of distal IIAs, to promote an adjunctive method of endovascular treatment.
Case reports

Patient 1
A 24-year old right-handed female patient with a history of intravenous (IV) heroin use presented to a tertiary referral center for evaluation of worsening infectious endocarditis. Initial presentation was 1 month prior, due to a psoas abscess and Streptococcus mitis (S. mitis) bacteremia. Systemic evaluation demonstrated mild aortic insufficiency and an aortic valve vegetation. Penicillin G was initiated. However, the patients later presented with worsening cardiac function and septic emboli to the right leg. Aortic valve replacement planning was initiated, which included brain magnetic resonance imaging (MRI) and angiography (A), as seen below in Figure 1 (a). This demonstrated an IIA in the left fronto-parietal region, along a distal cortical MCA branch. The neurological examination showed the system was intact.
We performed diagnostic cerebral angiography (Figure 1 (b) and Figure 1 (c)), including threedimensional (3-D) rotational angiography ( Figure 1(d) ). In a cortical left MCA branch, consistent with the precentral or central sulcal artery, a fusiform and widenecked IIA measuring 5.3 mm Â 4.7 mm was demonstrated. This location appeared consistent with either the primary motor or the pre-motor cortex. Given the eloquent surrounding cortex, an attempt at awake superselective Wada testing was made, in the hopes that parent vessel occlusion could be performed. Repeat diagnostic angiography was performed without the use of any sedating agents. Following placement of a 6F Neuron guide catheter (Penumbra Inc., Alameda, CA, USA) into the left internal carotid artery (ICA), road map access of the parent MCA vessel was obtained, with an Excelsior SL-10 microcatheter (Boston Scientific, Natick, MA, USA) via a Synchro2 microwire (Boston Scientific, Natick, MA, USA), as seen in Figure 1 (e). A baseline neurologic examination was performed, focusing on the right facial, arm and leg strength; as well as on sensation.
From a position just proximal to the IIA, we performed the provocative testing: 25 mg of sodium amytal was infused. Repeated neurologic testing demonstrated there were no new deficits. Next, we infused 20 mg of 2% lidocaine. Repeat neurologic testing again demonstrated no new deficits. These results indicated that there was likely a tolerance to vessel occlusion. Coil embolization of the IIA, followed with one Target 360 Ultra 3 mm Â 4 cm coil (Stryker, Kalamazoo, MI, USA) and one Target Helical 3 mm Â 4 cm coil (Stryker, Kalamazoo, MI, USA). We demonstrated complete occlusion of the IIA and the parent vessel ( Figure 1(f) ). Repeat neurological examinations continued, with no new deficits. The patient tolerated the procedure well and spent one night in the neurological intensive care unit. The patient underwent aortic valve replacement surgery 2 weeks later, without incident.
Patient 2
A 33-year old female with a significant history of IV drug abuse presented to the emergency department with fever, night sweats, back pain and right hand numbness. She was diagnosed with infectious endocarditis with significant valvular vegetations and bacteremia. We administered ceftriaxone intravenously. Due to the hand numbness, we performed a MRI/A, demonstrating a lesion, which was further characterized by computer tomography angiography (CTA) as a 4mm left M3 segment of the MCA IIA (Figures 2(a) and 2(b)). Plans for embolization without anesthesia were made (Figure 2(c) ). Following the placement of a 6F Envoy guide catheter (Codman and Shurtleff Inc., Raynham, MA, USA) into the distal left ICA, an ev3 Echelon-10 microcatheter (ev3 Neurovascular, Irvine, CA, USA) was placed into the proximal M3 branch harboring the IIA, via roadmap guidance and an Xpedion microwire (ev3 Neurovascular, Irvine, CA, USA).
A baseline neurological examination was performed, including detailed motor, sensory and speech examinations. Next, we infused 75 mg of sodium amytal, without any new neurological deficits; so 30 mg of 2% lidocaine was then infused. Initial examination demonstrated no new deficits; however, subtle word slurring was noted in a slightly delayed fashion, at the same time as the reflux of contrast and medication was noted on angiography. After 5 min, the patient's speech returned to baseline. These findings indicated there was likely safety in vessel occlusion, as the deficit only resulted from medication reflux to a more proximal location. A coil was placed in the lesion without deployment (Cerecyte 3 mm Â 4 cm coil; DePuy, Raynham, MA, USA). No new deficit was detected, so the coil was deployed. Two subsequent Deltapaq coils (DePuy, Raynham, MA, USA) were placed in the IAA, allowing for complete occlusion (Figure 2(d) ). The patient's neurologic examination remained at baseline throughout and after the procedure.
Discussion
IIAs represent a dangerous and difficult treatment dilemma for the treating physician. Traditional surgical clipping or excision had been the primary means of occlusion; however, due to the extremely fragile nature of the aneurysm wall and often the distal location of these IIAs, their open surgical cure has always proved quite challenging. Endovascular occlusion of the IIA or, if safe, the parent vessel itself, provides a more attractive treatment option and has now become the predominant method of attack for such lesions; however, IIAs occurring in the vascular supply to the eloquent cortex can make endovascular treatment, particularly parent vessel sacrifice, highly dangerous. By using the method of superselective Wada testing, the safety in treating these lesions can potentially be enhanced.
The initial presentation of an IIA is typically by to either headaches with fever or due to focal neurologic deficits from the septic infarcts. 5 Hemorrhagic presentations may occur in the form of subarachnoid hemorrhage or parenchymal hemorrhage. 4 Silent IIAs have been described in up to 20% of autopsies of at-risk patients. Without rigorous population data, the natural history of IIAs is difficult to fully appreciate. It is quite likely that with improved imaging resolution and increased clinical awareness, more asymptomatic IIAs are being discovered today, than in the years prior. Therefore, the true denominator of patients harboring an IIA is not known, making a true rupture rate calculation impossible; however, it remains known that a ruptured IIA results in a 30-80% mortality risk. Size does not appear to predict the risk of IIA rupture. 1 Given the lack of controlled data to provide an understanding of rupture risks, no cohesive standards exist to guide the treatment of IIAs. Some combined form of long-term intravenous antibiotics (typically the same course necessary for the associated endocarditis), surgical occlusion, or endovascular treatment is typically utilized.
If a reasonable chance for meaningful recovery exists following IIA rupture, the recommendation remains to pursue aggressive securement of the IIA. If a spaceoccupying hematoma exists, open surgical decompression with parent vessel sacrifice remains the preferred option. If there is no need for open surgical decompression, endovascular occlusion of the IIA or the parent vessel both appear reasonable.
The decision tree for treatment of unruptured IIAs is more difficult. Disappearance of IIAs with antibiotic treatment alone has been described in 29-33% of selected patients; 10, 11 however, in those same reports, 17-18.5% of IIAs decreased in size, 17-22% of IIAs increased in size and 15-33% of IIAs persisted unchanged. Thus, given this unpredictable response to antibiotics and the known high morbidity and mortality of IIA rupture, aggressive occlusion of treatable lesions remains recommended. If the IIA involves the entire arterial circumference, lies proximal in the parent vessel and the artery cannot tolerate sacrifice; then conservative therapy with antibiotics may remain the only reasonable option. 1 In those cases of both ruptured and unruptured IIAs, the authors favor immediate treatment for the ruptured IAAs and close observation for IAAs. If there is no response to antibiotic treatment within a few weeks, we elect to treat even the unruptured IAAs.
Parent artery occlusion remains the preferred choice for complex IIAs involving the entire parent vessel wall and located distally along the vascular course. This can be performed in the non-eloquent cortex with relatively low morbidity, utilizing any known embolization agent (i.e. NBCA, Onyx, etc.). Many authors prefer to occlude parent vessels with short detachable coils, as this may allow for more operator control as well as allow for improved distal collateral flow. 12 Parent vessel occlusion of IIAs in the eloquent cortex carries a higher risk of resultant neurologic dysfunction. Super-selective provocative testing is a described technique involving the injection of a pharmacologic agent into a target vessel of a non-sedated patient, to assess the potential deficits of occluding that target vessel. Use of this technique has been described in the treatment of spinal, 9 external carotid circulation lesions, 8 as well as arteriovenous malformations; 13, 14 however, this technique has not been well described in the assessment of IIA parent vessel occlusion. This technique requires an awake, non-sedated patient who can provide a reliable neurological exam before, during and after the procedure. Adjunctive monitors, such as electroencephalogram (EEG), motor-evoked-potentials, or sensory-evoked-potentials may be used, as well.
Amobarbital is a short-acting barbiturate that inhibits post-synaptic neurons via the gamma-aminoburyic acid A (GABAa) receptor. These GABAa receptors are prevalent throughout the cortical gray matter; however, cerebral white matter tracts are largely devoid of GABAa receptors. Thus, sodium amobarbital will promote GABAa receptors to block cortical gray matter signal transmission, but white matter transmission remains unaltered. In contrast, lidocaine blocks voltage-gated sodium channels on all nerve cell membranes, thus it will decrease signal transmission in both the gray and white matter. 15 Sodium amobarbital is reconstituted to 50 mg/mL with sterile saline and a 1:1 mixture with the contrast agent of choice is created. Following the neurologic examination, 25-125 mg is injected from the microcatheter under fluoroscopic evaluation, to ensure a lack of reflux. Repeat examination is conducted: If no symptoms develop over the next 5 minutes, the test is considered negative. Next, a 2% solution of cardiac lidocaine is buffered with sodium bicarbonate at a 9:1 ratio, and then drawn into a 1:1 contrast mixture. Typically, 20 mg of lidocaine is given for each test under fluoroscopic evaluation. Again, the lack of symptoms within 5 minutes indicates a negative test. 8 If symptoms develop, they typically resolve within 15 minutes, most often much earlier.
Temporary artery occlusion using a balloon (e.g. Scepter, MicroVention, Tustin, CA, USA) may be an option in selected cases of IAAs; however, there is some concern about causing arterial injury or rupture of the artery using balloon angioplasty, due to the location of the IAA in the very distal middle cerebral artery territory, and a potential for increased vascular fragility in the setting of infectious vascular disease.
As seen in the above case illustrations, this technique can be applied rapidly and safely to a cooperative patient, to validate parent vessel occlusion of IIAs in a presumed eloquent cortex. Both our patients tolerated the procedure without developing new neurologic deficits. Slight variations in dosing were chosen between the two cases, due to baseline weight differences between these patients. While both patients tolerated the provocative testing, had they failed some component of the testing, a clinical decision would need to have been made regarding the possible deficit versus the risk of treatment. The monitoring of evoked potentials in such cases may provide increased information to guide this decision.
Conclusions
IIAs are rare but potentially lethal lesions. With improved imaging quality and increased screening protocols for asymptomatic patients with systemic infections, an increased proportion of IIAs will likely be diagnosed in the coming years. Current treatment recommendations are based on non-standardized data and involve antibiotics, surgical obliteration, or endovascular occlusion. Future data may demonstrate an increased role for antibiotic treatment and observation; however, currently it is not known which lesions can be simply observed. This, coupled with the high mortality of a ruptured IIA, means that aggressive treatment will remain a main-stay of current treatment. Surgical indications are rapidly waning, while endovascular treatment has been proven to be effective and safe. An IIA in an eloquent cortical location does not preclude effective endovascular treatment. By utilizing a superselective provocative testing technique that is often used in the embolization of other lesions, we present a safe and effective technique to improve the patient selection in treating these distally-located IIAs in a presumed eloquent cortex.
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